Abstract
Malaria remains one of the deadliest infectious diseases worldwide and continues to infect hundreds of millions of individuals each year. Here we report the discovery and derivatization of a series of 2,6-dibenzylidenecyclohexanones targeting the chloroquine-sensitive 3D7 strain of Plasmodium falciparum. While the initial lead compound displayed significant toxicity in a human cell proliferation assay, we were able to identify a derivative with no detectable toxicity and sub-micromolar potency.
| Original language | English |
|---|---|
| Article number | 128216 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 47 |
| DOIs | |
| State | Published - Sep 1 2021 |
Bibliographical note
Publisher Copyright:© 2021 The Author(s)
Funding
This work was supported by the Bill and Linda Frost Fund at California Polytechnic State University (no associated grant number).
| Funders |
|---|
| Bill and Linda Frost Fund |
| California State Polytechnic University Pomona |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 2,6-Dibenzylidenecyclohexanone
- Malaria
- Michael system
- Plasmodium falciparum
- Structure activity relationship
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Molecular Biology
- Pharmaceutical Science
- Drug Discovery
- Clinical Biochemistry
- Organic Chemistry
Fingerprint
Dive into the research topics of 'Antimalarial activity of 2,6-dibenzylidenecyclohexanone derivatives'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver